Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Core Insights - Immunovant, Inc. reported corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2025, highlighting its focus on autoimmune diseases and the development of IMVT-1402 [1] Recent Highlights and Upcoming Milestones - Leadership changes were announced in April 2025, with Eric Venker appointed as CEO and Tiago Girao as CFO, as Roivant increases operational involvement [2] - IMVT-1402 is being developed for six indications, including registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjögren's disease, along with a proof-of-concept trial in cutaneous lupus erythematosus [2] - Positive results were reported in March 2025 from batoclimab studies for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with significant improvements in clinical outcomes [3][4] Financial Highlights for Fiscal Fourth Quarter - As of March 31, 2025, cash and cash equivalents totaled approximately $714 million, providing sufficient runway for ongoing clinical trials [6] - Research and development expenses increased to $93.7 million for the quarter, up from $66.1 million in the same period the previous year, primarily due to clinical trial activities [7] - General and administrative expenses rose to $20.2 million, compared to $14.8 million in the prior year, driven by higher personnel-related expenses and professional fees [8] Financial Highlights for Fiscal Year - For the fiscal year ended March 31, 2025, research and development expenses were $360.9 million, up from $212.9 million the previous year, reflecting increased clinical trial costs [11] - General and administrative expenses for the fiscal year were $77.2 million, compared to $57.3 million in the prior year, attributed to higher personnel-related and professional fees [13] - The net loss for the fiscal year was $413.8 million ($2.73 per share), compared to a net loss of $259.3 million ($1.88 per share) the previous year [14]